About this episode

Dr. Peter Fedichev discusses GERO's innovative approaches to slowing aging and treating age-related diseases using AI and physics.

Dr. Peter Fedichev is the co-founder and CEO of GERO , a Singapore-based biotech startup that uses physics-informed AI and massive human health datasets to discover drugs aimed at slowing down aging and treating age-related diseases. In the 2nd part of this episode, Peter explains how Gero builds generative models of human health to predict disease trajectories and identify shared biological drivers across multiple chronic conditions. He discusses why metabolic dysfunction and inflammation represent promising intervention points, how partnerships with pharma companies like Chugai accelerate translation, and why companion dogs could become the proving ground for longevity therapeutics. Peter also shares his perspective on AI-driven drug discovery, arguing that target identification, not molecule generation, will create the greatest value. He outlines Gero’s open-source approach, fundraising journey, and vision for a future where therapies can meaningfully slow the aging process itself. Host: John Joson Ng Editors: Dillon Chew, Chi Dam, Vasilina Gedzun 00:00 Gero Roadmap Overview 00:35 Predicting Disease Trajectories 03:03 Super Targets Strategy 05:07 Ozempic Market Wakeup 07:28…

People in this episode

Host: John Joson Ng

Guest: Dr. Peter Fedichev

Topics covered

• human aging
• AI in drug discovery
• biotech
• disease prediction
• partnerships in pharma
• longevity therapeutics

Keywords

• aging
• AI
• drug discovery
• biotech
• disease trajectories
• metabolic dysfunction
• inflammation
• longevity
• Gero
• Chugai

Mentioned in this episode

Organizations: GERO, Chugai

More episodes of Nucleate Singapore Pulse

• Charting Singapore's Biotech Pipeline with Dr. Katherine Wang of A*STAR's STDR · July 19, 2026 · 41 min
• Rewriting human aging with Physics and AI with Dr. Peter Fedichev of Gero (Part 1) · June 16, 2026 · 31 min

Explore listener stats, chart rankings, contacts and more on the Nucleate Singapore Pulse podcast page.